

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd

OM protein - protein search, using sw model

Run on: March 1, 2001, 15:47:18 ; Search time 210.42 Seconds  
(without alignments)  
7.638 Million cell updates/sec

Title: US-09-331-631A-7\_COPY\_34\_80  
Page: 359

Sequence: 1 YERDPRQYEQCQRCESEA.....QCEQRCERFKEQQRQEEE 47

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 268485 seqs, 34193795 residues

Total number of hits satisfying chosen parameters: 268485

```
Minimum DB seq length: 0
Maximum DB seq length: 20000000000
```

Post-processing: Minimum Match 0%

## Listing first 45 summaries

Database :

1:	/SIDS1/gcgdata/genseq/genseq/AI1980.DAT *
2:	/SIDS1/gcgdata/genseq/genseq/AI1981.DAT *
3:	/SIDS1/gcgdata/genseq/genseq/AI1982.DAT *
4:	/SIDS1/gcgdata/genseq/genseq/AI1983.DAT *
5:	/SIDS1/gcgdata/genseq/genseq/AI1984.DAT *
6:	/SIDS1/gcgdata/genseq/genseq/AI1985.DAT *
7:	/SIDS1/gcgdata/genseq/genseq/AI1986.DAT *
8:	/SIDS1/gcgdata/genseq/genseq/AI1987.DAT *
9:	/SIDS1/gcgdata/genseq/genseq/AI1988.DAT *
10:	/SIDS1/gcgdata/genseq/genseq/AI1989.DAT *
11:	/SIDS1/gcgdata/genseq/genseq/AI1990.DAT *
12:	/SIDS1/gcgdata/genseq/genseq/AI1991.DAT *
13:	/SIDS1/gcgdata/genseq/genseq/AI1992.DAT *
14:	/SIDS1/gcgdata/genseq/genseq/AI1993.DAT *
15:	/SIDS1/gcgdata/genseq/genseq/AI1994.DAT *
16:	/SIDS1/gcgdata/genseq/genseq/AI1995.DAT *
17:	/SIDS1/gcgdata/genseq/genseq/AI1996.DAT *
18:	/SIDS1/gcgdata/genseq/genseq/AI1997.DAT *
19:	/SIDS1/gcgdata/genseq/genseq/AI1998.DAT *
20:	/SIDS1/gcgdata/genseq/genseq/AI1999.DAT *
21:	/SIDS1/gcgdata/genseq/genseq/AI2000.DAT *

**Pred. No.** is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	258	100.0	525	19	W62831	Theobroma cacao am
2	258	100.0	566	13	R20181	Sequence encoded b
3	157	60.9	625	19	W62830	Macadamia integrifl
4	157	60.9	666	19	W62829	Macadamia integrifl
5	154	59.7	666	19	W62828	Macadamia integrifl
6	124	48.1	590	19	W62832	Gossypium hirsutum
7	94	36.4	611	20	V29039	T. gondii immunoge
8	92	35.7	562	16	R70491	Leucocytozoan prot
9	86	33.3	1898	20	V30795	A human trichohyal
10	85	32.9	1162	21	W58500	HHV8 ORF 73 protei
11	82.5	32.0	186	18	W26556	Trypanosoma cruzi
12	82.5	32.0	186	20	V23298	Trypanosoma cruzi a

13	82	31.8	1135	21	Y68784	Amino acid sequence
14	82	31.8	1233	20	Y55954	Mouse STE20-related
15	82	31.8	1239	20	Y55931	Human ZC1 protein.
16	80	31.0	86	20	W95073	GST-HD fusion prot.
17	80	31.0	86	20	W95078	GST-HD fusion prot.
18	80	31.0	94	20	W95075	GST-HD fusion prot.
19	80	31.0	94	20	W95080	GST-HD fusion prot.
20	78	30.6	910	20	Y22191	Mouse brain cNG-1
21	78	30.2	360	17	W03627	Human follicle sticle
22	77	29.8	371	20	W73369	Epitope tagged rppp
23	77	29.8	412	17	W03626	Human lysoleutropin
24	76.5	29.7	1297	20	Y55932	Human ZC2 protein.
25	76	29.5	482	20	Y07067	Renal cancer assoc
26	76	29.5	740	13	R27530	Plasmodium falcipara
27	76	29.5	740	16	R68838	Plasmodium falcipara
28	76	29.5	1360	21	Y85263	Human protein kinase
29	75	29.1	1299	21	Y58633	Protein regulating
30	74.5	28.9	314	20	W68499	Human stomach carc
31	74.5	28.9	326	20	Y20109	B. burgdorferi ant
32	74.5	28.9	347	20	Y20108	B. burgdorferi ant
33	74	28.7	28	19	W62841	Stenocarpus sinuati
34	74	28.7	1132	18	W30749	Rat YRS21 gene pro
35	74	28.7	1132	17	R97866	Chicken leucocytos
36	74	28.7	1326	17	Y55933	Human ZC3 protein.
37	73.5	28.5	303	15	R60054	Diofilariia immitis
38	73.5	28.5	346	20	Y20115	B. burgdorferi ant
39	73.5	28.5	373	20	Y20114	B. burgdorferi ant
40	73	28.3	1197	21	Y57445	Mouse Ees2 protein
41	73	28.3	1658	21	Y57450	Mouse Ees21 protei
42	73	28.3	2074	21	Y54319	Amino acid sequenc
43	72.5	28.1	288	20	W72759	Recombinant human
44	72	27.9	1012	20	Y17406	Human atrophin-1 r
45	71.5	27.7	905	18	W31186	Human p160 polypep

## ALIGNMENTS

RESULT	1
ID	W62831
	W62831 standard; Protein; 525 AA.
XX	
XX	W62831;
XX	
XX	27-OCT-1998 (first entry)
XX	
XX	Theobroma cacao antimicrobial protein.
DE	
XX	antimicrobial protein; infestation; control.
XX	
OS	Theobroma cacao.
XX	
XX	W09827805-A1.
PN	
XX	02-JUL-1998.
XX	
PD	
XX	22-DEC-1997; 97WO-A000874.
PF	
XX	
PR	20-DEC-1996; 96AU-0004275.
XX	
XX	(RETR-) COOP RES CENT TROPICAL PLANT PATHOLOGY.
PA	
PI	Bower NT, Goulter KC, Green JL, Manners JM, Marcus JP.
XX	
DR	WPI; 1998-377279/32.
XX	
PT	Novel anti-microbial protein from e.g. Macadamia integrifolia -
XX	useful for controlling microbial infestations of plants or mammals
XX	Claim 1; Page 47-49; 96pp; English.
CC	The sequence is that of an antimicrobial protein which can
CC	be used to control microbial infestations in plants and mammalian



PN	WO9827805-A1.
XX	
PD	02-JUL-1998.
XX	
PF	22-DEC-1997; 97WO-AU00874.
XX	
PR	20-DEC-1996; 96AU-0004275.
XX	
PA	(RETR-) COOP RES CENT TROPICAL PLANT PATHOLOGY.
XX	
PI	Bower NI, Goulter KC, Green JL, Manners JM, Marcus JB;
XX	
DR	WPI: 1998-377279/32.
DR	N-PADB; V42311.
XX	
PT	Novel anti-microbial protein from e.g. <i>Macadamia integrifolia</i> -
XX	useful for controlling microbial infestations of plants or mammals
PS	Claim 1; Page 39-41; 96pp; English.
XX	
CC	The sequence is that of an antimicrobial protein which can
CC	be used to control microbial infestations in plants and mammalian
CC	animals.
XX	
SQ	Sequence 666 AA;

Query Match	60.9%	Score 157	DB 19	Length 666
Best Local Similarity	53.3%	Pred. No. 4	9e-10	
Matches	24	Conservative	12	Mismatches 9
				Indels 0
				Gaps 0
OY	2	ERDPRDTEGCRCRCSEATERED	EOCEORCEKTKEDQROEE	46
db	119	qrdpqgqyeqccqrhnetprlmqtcrcqrccreeryekkrqgk		163

RESULT	5
ID	W62828 standard; Protein; 666 AA.
XX	
AC	W62828;
XX	
DT	27-OCT-1998 (first entry)
XX	
DE	Macadamia integrifolia antimicrobial protein.
XX	
KM	antimicrobial protein; infestation; control.
XX	
OS	Macadamia integrifolia.
XX	
Key	Location/Qualifiers
FH	1..28
FT	/note= "signal peptide"
FT	29..666
FT	/note= "mature protein"
FT	
XX	
PN	W09827805-A1.
XX	
PD	02-JUL-1998.
XX	
PF	22-DEC-1997; 97WO-AU00874.
XX	
PR	20-DEC-1996; 96AU-0004275.
XX	
PA	(RETR-) COOP RES CENT TROPICAL PLANT PATHOLOGY.
XX	
PI	Bower NL, Goulter KC, Green JL, Manners JM, Marcus JP;
XX	
DR	WPI; 1998-377279/32.
XX	
XX	N-PSDB; V42310.
XX	
PT	Novel anti-microbial protein from e.g. Macadamia integrifolia - useful for controlling microbial infestations of plants or mammals

XX  
PS Claim 1; Page 34-36; 96pp; English.  
XX  
XX The sequence is that of an antimicrobial protein which can  
CC be used to control microbial infestations in plants and mammalian  
CC animals.  
XX  
SQ Sequence 666 AA.

Query Match 59.7%; Score 154; DB 19; Length 666;  
Best Local Similarity 51.1%; Pred. No. 1e-09;  
Matches 23; Conservative 13; Mismatches 9; Gaps 0;

QY 2 ERDPROYEQCQRCESEATEEREQEQCEQRCEREYKEQDROEE 46  
:::|||||: | | : |:||| |:::|:|:  
Db 119 qrdpqyqeqckhcgrreretphmqtcqgrcerryekrkgqk 163

RESULT	6
ID	W62832
XX	W62832 standard; Protein; 590 AA.
XX	
AC	W62832;
XX	
DT	27-OCT-1998 (first entry)
XX	
DE	Gossypium hirsutum antimicrobial protein.
XX	
KW	antimicrobial protein; infestation; control.

05 *Gossypium hirsutum.*

PN W09827805-A1.

PD 02-JUL-1998.

PF 22-DEC-1997; 97WO-AU00874.

PR 20-DEC-1996; 96AU-0004275.

PA (RETR-) COOP RES CENT TROPICAL PLANT PATHOLOGY.

PI Bower NI, Goulter KC, Green JL, Mannors JM, Marcus JP;

DR WPI; 1998-377279/32.

PT Novel anti-microbial protein from e.g. *Macadamia integrifolia* -

XX

XX

CC be used to control microbial infestations in plants and mammalian

XX

Query Match	48.1%	Score 124;	DB 19;	Length 590;
Best Local Similarity	46.3%	Pred. No. 2e-06;		
Matches 19; Conservative	12;	Mismatches 10;	Indels 0;	Gaps 0;

Dy 4 DPROYECCQRCESEATEERDEOCEDRCEREYKEORQO 44  
||::|||:||||: ::|||:|||: |: :| |: ||  
Db 36 dppkryedcrrrcwdlrgqkeqqceescksygkedqq 76

RESULT	7
Y29039	
ID	Y29039 standard; Protein; 611 AA
XX	
AC	Y29039;

XX 24-SEP-1999 (first entry)  
XX  
XX T. gondii immunogenic protein.  
XX  
XX Immunogenic protein; Toxoplasma gondii protein; oocyst shedding; cat;  
XX T. gondii infection; enteric apicomplexa oocyst; Cryptosporidium oocyst;  
XX Toxoplasma oocyst.  
XX  
XX Toxoplasma gondii.  
XX  
XX  
XX WO9932633-A1.  
XX  
XX 01-JUL-1999.  
XX  
XX 18-DEC-1998; 98WO-US27137.  
XX  
XX 19-DEC-1997; 97US-0994825.  
XX  
XX (HESK-) HESKA CORP.  
XX  
XX Lutz SB, Milhausen MJ, Ng RK;  
XX WPI; 1999-418930/35.  
XX N-PSDB; X91242.  
XX  
XX New isolated Toxoplasma gondii nucleic acids used, e.g. to treat  
XX infection caused by this microorganism  
XX  
XX  
XX Claim 29; Page 227-229; 381pp; English.  
XX  
XX The invention provides isolated Toxoplasma gondii nucleic acids that  
XX encode immunogenic polypeptides. The T. gondii nucleic acid molecules,  
XX immunogenic proteins and antibodies to the proteins can be used to  
XX inhibit T. gondii oocyst shedding in a cat due to infection with  
XX T. gondii. They can be used for preventing T. gondii infection and for  
XX preventing the spread of T. gondii infection. They can also be used for  
XX detecting T. gondii infection. The detection method can be used to detect  
XX parasite cysts or oocysts in feces, e.g. from enteric apicomplexa oocysts  
XX such as Cryptosporidium oocysts and Toxoplasma oocysts.  
XX  
XX Sequence 611 AA;  
XX

	Query Match	Similarity	36.4%; Score 94; DB 20;	Length 611;
	Best Local	Similarity	45.2%; Pred No. 0.0043;	
	Matches	19; Conservative	11; Mismatches	12; Indels 0; Gaps 0.
QY	6 RQQVEQCQRRCSEATEEREDQEQRCERCERYKEEQDQDEEE	47		
	::: :::::     :::::     :::  ::			
Dd	456 reeeerrrrveeekkereregeererrrrveeekkereregee	497		
RESULT	8			
ID	R70491 standard; Protein; 562 AA.			
XX	R70491			
AC				
XX				
XX				
DT	19-DEC-1995 (first entry)			
XX				
DE	Leucocytozoan protozoa structural protein epitope.			
KW	leucocytozoan protozoa; structural protein; epitope; vaccine; fowl;			
KW	leucocytozanosis; treatment.			
XX				
OS	Leucocytozoan protozoa sp.			
XX				
PX	JP07089995-A.			
PD				
XX				
PD	04 - APR - 1995.			
XX				
PF	10-SEP-1993; 93JP-0226078.			

XX	
PR	10-SEP-1993; 93JP-0226078.
XX	
PA	(DOBU-) DOBUTSUO SEIBUTSUGAKUTEKI SEIZAI KYOKAI.
FA	(NISS-) NISSEIKEN KK.
XX	
DR	WPI; 1995-167252/22.
DR	N-PSDB; Q87587.
XX	
PT	Immune inducing polypeptide against Leucocytozoan protozoa - useful
PT	in production of vaccines for treatment of Leucocytozoanosis in
PT	fwl.
XX	
PS	Claim 1; Page 12-14; 20pp; Japanese.
XX	
CC	R70491-93 are polypeptides having a whole or partial epitope of a
CC	structural protein of Leucocytozoan protozoa encoded by Q87587-89.
CC	The polypeptides and DNA encoding them are useful in the production
CC	of vaccines for the treatment of Leucocytozoanosis of fowl.
XX	
XX	
Sequence	562 AA;
Sequence	

```

Query Match      35.7%; Score 92; DB 16; Length 562;
Best Local Similarity 39.1%; Pred. No. 0.0065;
Matches 18; Conservative 14; Mismatches 14; Indels 0; Gaps 0;

Oy 2 EDDPQQTCCRCSEATEEREDQCCRCERETKEDQROQEE 47
    : : : : : : : : : : : : : : : : : : : : : :
db 41 ekeeeeeeeggeeggeeeveegdeeeegdeeeeeeekkeee 86
    : : : : : : : : : : : : : : : : : : : : : :

```

[illegible]

DT 25-NOV-1999 (first entry)  
XX  
DE A human trichohyalin (TRHY) protein

KW Human; trichohyalin; TRHY; protein; tissue structure; wound healing  
 KW terminally differentiating epidermal tissue; proteinaceous gel;  
 KW breast implant.

Homo sapiens.

PN US5958752-A.

PD 28-SEP-1999

PF 14-FEB-1997

PR 30-APR-1993

PA (USSH ) US I

PI Kim I, Chur

AA WPI; 1999-56  
DR

DR N-PSDB; 222

PT	human	clinical
PT	wound	healing

PS Disclosure:

XX The present

CC The protein  
CC and is invol

CC tissue. The

ing;

**omotes**

5

ue,



RESULT	12
ID	Y23298 standard; Protein: 186 AA.
XX	Y23298
AC	Y23298;
XX	
DT	31-AUG-1999 (first entry)
XX	
DE	Trypanosoma cruzi antigen amino acid sequence.
XX	
KW	Trypanosoma cruzi epitope; Trypanosoma cruzi infection; antigen; vaccine; Chagas' disease.
XX	
OS	Trypanosoma cruzi.
PN	WO931246-A1.
PD	24-JUN-1999.
XX	
PF	04-DEC-1998; 98WO-US25871.
XX	
PR	18-DEC-1997; 97US-0993674.
XX	
PA	(CORI-) CORIXA CORP.
P1	Houghton RL, Lodes MJ, McNeill PD, Reed SG, Skeiky YAM;
P1	Smith JM;
XX	
DR	WPI: 1999-405035/34.
XX	
P7	New isolated Trypanosoma cruzi epitopes
PS	Disclosure: Page 79; 103pp; English.
XX	
CC	The specification describes new Trypanosoma cruzi epitopes. A method for detecting Trypanosoma cruzi infection in a biological sample comprises contacting the sample with a polypeptide comprising an epitope of a TC antigen, or a variant of the antigen that differs only in conservative substitutions and/or modifications and detecting the presence of antibodies that bind to the polypeptide in the sample, thereby detecting TC infection. The TC polypeptides can be used in vaccines for inducing protective immunity against Chagas' disease in a patient. The polypeptides and antibodies can also be used for detecting TC infection. Y23292-301 represent Trypanosoma cruzi antigens.
CC	
CC	
SO	Sequence 186 AA;
Query Match	32.0%; Score 82.5; DB 20; Length 186;
Best Local Similarity	40.8%; Pred. No. 0.025;
Matches 20; Conservative 7; Mismatches 19; Indels 3; Gaps 1	
OY	2 EMDRQOYECCORCESEA---TEEREDQCRCREKKEQROQE 47
DB	II I : I : I I I III : : I I II : I I 69 errarreaeraqraeeratqraeeraarraetrakeerawgeae 117
RESULT	13
ID	Y68784 standard; Protein: 1135 AA.
XX	Y68784
AC	Y68784;
XX	
DT	16-MAY-2000 (first entry)
XX	
DE	Amino acid sequence of a human phosphorylation effector PHS-16.
XX	
KW	Human; phosphorylation effector; PHS; proliferative disorder; immune disorder; neuronal disorder.
XX	
OS	Homo sapiens.
XX	
Key	Location/Qualifiers

FT	Modified-site	9	"potential phosphorylation site"
FT	Modified-site	17	"potential phosphorylation site"
FT	Region	/note= 31..54	"potential phosphorylation site"
FT	Modified-site	/note= 33	"protein kinase signature sequence"
FT	Modified-site	/note= 59	"potential glycosylation site"
FT	Modified-site	/note= 59	"potential phosphorylation site"
FT	Modified-site	/note= 59	"potential phosphorylation site"
FT	Modified-site	/note= 77	"potential phosphorylation site"
FT	Modified-site	/note= 112	"potential phosphorylation site"
FT	Modified-site	/note= 124	"potential phosphorylation site"
FT	Region	/note= 129..182	"potential phosphorylation site"
FT	Region	/note= 149..161	"protein kinase signature sequence"
FT	Modified-site	/note= 187	"protein kinase signature sequence"
FT	Active-site	/note= 190..200	"potential phosphorylation site"
FT	Active-site	/note= 214..236	"tyrosine kinase catalytic site"
FT	Modified-site	/note= 222	"tyrosine kinase catalytic site"
FT	Modified-site	/note= 235	"potential phosphorylation site"
FT	Modified-site	/note= 259	"potential phosphorylation site"
FT	Modified-site	/note= 264	"potential phosphorylation site"
FT	Modified-site	/note= 309	"potential phosphorylation site"
FT	Modified-site	/note= 319	"potential phosphorylation site"
FT	Modified-site	/note= 321	"potential phosphorylation site"
FT	Modified-site	/note= 323	"potential phosphorylation site"
FT	Modified-site	/note= 324	"potential phosphorylation site"
FT	Modified-site	/note= 326	"potential phosphorylation site"
FT	Modified-site	/note= 351	"potential phosphorylation site"
FT	Modified-site	/note= 467	"potential phosphorylation site"
FT	Modified-site	/note= 543	"potential phosphorylation site"
FT	Modified-site	/note= 550	"potential phosphorylation site"
FT	Modified-site	/note= 554	"potential phosphorylation site"
FT	Modified-site	/note= 570	"potential phosphorylation site"
FT	Modified-site	/note= 572	"potential glycosylation site"
FT	Modified-site	/note= 624	"potential phosphorylation site"
FT	Modified-site	/note= 625	"potential phosphorylation site"
FT	Modified-site	/note= 632	"potential phosphorylation site"
FT	Modified-site	/note= 681	"potential phosphorylation site"
FT	Modified-site	/note= 682	"potential phosphorylation site"
FT	Modified-site	/note= 688	"potential phosphorylation site"

FT	Modified-site	/note= "potential phosphorylation site"
FT	689	/note= "potential phosphorylation site"
FT	706	/note= "potential phosphorylation site"
FT	718	/note= "potential phosphorylation site"
FT	720	/note= "potential glycosylation site"
FT	726	/note= "potential phosphorylation site"
FT	811	/note= "potential phosphorylation site"
FT	815	/note= "potential phosphorylation site"
FT	836..1115	/note= "potential phosphorylation site"
FT	Domain	/note= "NIK1-like kinase domain"
FT	898	/note= "potential phosphorylation site"
FT	931	/note= "potential phosphorylation site"
FT	958	/note= "potential phosphorylation site"
FT	978	/note= "potential phosphorylation site"
FT	999	/note= "potential phosphorylation site"
FT	1012	/note= "potential phosphorylation site"
FT	1067	/note= "potential phosphorylation site"
FT	1113	/note= "potential glycosylation site"
FT	Modified-site	/note= "potential phosphorylation site"
PN	MO200006728-A2.	
XX	10-FEB-2000.	
XX	28-JUL-1999;	99MO-US17132.
XX	28-JUL-1998;	98US-0123494.
PR	14-SEP-1998;	98US-0152814.
PR	14-OCT-1998;	98US-0173482.
PR	03-NOV-1998;	98US-0106889.
PR	19-NOV-1998;	98US-0109093.
PR	22-DEC-1998;	98US-0113796.
PR	12-JAN-1999;	99US-0173482.
PR	12-JAN-1999;	99US-0229005.
XX	(INCYTE PHARM INC.	
XX	Hillman JL, Lai P, Tang YT, Corley NC, Guegler KJ, Baughn MR;	
PI	Patterson C, Bandman O, Au-Young J, Gorgone GA, Yue H, Azimzai Y,	
PI	Reddy R, Lu DM, Shih LL;	
XX	WPI: 2000-183125/16.	
DR	N-PSDB; 246153.	
XX		
PT	New human phosphorylation effectors useful for the diagnosis, treatment	
PT	and prevention of proliferative, immune and neuronal disorders -	
XX		
PS	Claim 1: Page 98-100; 142pp; English.	
XX		
CC	y68769-95 and y68797-99 represent human phosphorylation effectors (PHSP)	
CC	designated PHSP1-PHSP11 (the protein sequence for PHSP28 is not given	
CC	in the specification). The sequences were isolated from cDNA libraries	
CC	prepared from various human tissues. The PHSP proteins are useful for	
CC	the diagnosis, treatment and prevention of proliferative disorders,	
CC	immune disorders and neuronal disorders. The PHSP proteins form	
CC	pharmaceutical compositions which useful for treating or preventing	
CC	disorders associated with decreased PHSP expression/activity. PHSP	
CC	antagonists are useful for treating or preventing disorders associated	
CC	with increased PHSP expression/activity.	

XX	SQ	Sequence	1135 AA:
OY		Query Match	31.8%; Score 82; DB 21; Length 1135;
		Best Local Similarity	45.7%; Pred. No. 0.17;
		Matches 21; Conservative	11; Mismatches 10; Indels 4; Gaps 2
D6	2	ERDPROOYECCRCSEATFEREOECRCREKVEGOOROE	47
		:              :   :   :   :   :	
		416 eearqteqrtege--ekrtleer--rkeeeerrae	457
RESULT	14		
ID	Y55954	standard; Protein; 1233 AA.	
AC	Y55954;		
DT	18-FEB-2000	(first entry)	
DE	Mouse STE20-related protein kinase NIK_m.		
KW	Antiinflammatory; antiarthritic; antiinflammatory; antiallergic; osteopathic;		
KW	antiproliferative; antiantibiotic; antineoplastic; immunosuppressive;		
KW	neuroprotective; cardiac; cerebroprotective; cytostatic; antidiabetic;		
KW	vulnerability; STE20: protein kinase; STIK2; STIK3; STIK4; STIK5; STIK6; STIK7		
KW	ZC1, ZC2, ZC3, ZC4, KMS2, SULK1, SULK3, GSK2, PAK4, PAK5; antagonist;		
KW	antibody; gene therapy; rheumatoid arthritis; atherosclerosis; asthma;		
KW	inflammatory bowel disease; Crohn's disease; osteoarthritis; psoriasis;		
KW	rheinitis; autoimmunity; organ transplantation; multiple sclerosis;		
KW	myocardial infarction; cardiovascular disease; stroke; renal failure;		
KW	oxidative stress-related neurodegenerative disorder; Parkinson's disease		
KW	amyotrophic lateral sclerosis; Leigh syndrome; cancer; cardiomyopathy;		
KW	ischemic disorder; inflammation; diabetes mellitus; fibrosis; mitosis;		
KW	mesangial disorder; growth regulation; wound healing; T cell activation;		
OS	Mus sp.		
PN	W09953036-A2.		
PD	21-OCT-1999.		
PE	13-APR-1999; 99WO-US08150.		
PR	14-APR-1998; 98US-0081784.		
PA	(SUGEN-) SUGEN INC.		
PI	Piomman G, Martinez R, Whyte D;		
PT	WPI; 1999-611301/52.		
PS	Novel kinase-related polypeptides used for the diagnosis and treatment		
XX	of kinase-related diseases and disorders _		
XX	Disclosure; Page 339-343; 387pp; English.		
XX	This sequence represents a novel STE20-related protein kinase. The		
XX	invention relates to nucleic acid molecule encoding a kinase polypeptide		
XX	selected from STIK2, STIK3, STIK4, STIK5, STIK6, STIK7, ZC1, ZC2, ZC3,		
XX	ZC4, KMS2, SULK1, SULK3, GSK2, PAK4 and PAK5. The proteins are used to		
XX	identify agonists and antagonists, and to raise antibodies. The		
XX	polynucleotides are useful in gene therapy protocols. The polynucleotides,		
XX	polypeptides, antibodies, antagonists and agonists may be used to treat		
XX	diseases such as immune-related disorders and diseases (e.g. rheumatoid		
XX	arthritis, atherosclerosis, chronic inflammatory bowel disease (e.g.		
XX	Crohn's disease), asthma, osteoarthritis, psoriasis, atherosclerosis (e.g.		
XX	rheinitis, autoimmunity, and organ transplantation), chronic inflammatory		
XX	pelvic disease, multiple sclerosis, organ transplantation, myocardial		
XX	infarction, cardiovascular disease, stroke, renal failure, oxidative		
XX	stress-related neurodegenerative disorders (e.g. amyotrophic lateral		

